- Home
- SLP vs PBYI Comparison
SLP vs PBYI Comparison
Compare SLP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLP | PBYI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.9M | 364.9M |
| IPO Year | 1996 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SLP | PBYI |
|---|---|---|
| Price | $18.22 | $8.29 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $24.00 | N/A |
| AVG Volume (30 Days) | ★ 673.1K | 364.6K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $59,577,000.00 | $27,685,000.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $42.42 | ★ N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $11.09 | $3.03 |
| 52 Week High | $21.01 | $8.44 |
Technical Indicators
Market Signals| Indicator | SLP | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 63.41 | 62.06 |
| Support Level | $17.74 | $6.50 |
| Resistance Level | $18.62 | $8.42 |
| Average True Range (ATR) | 0.16 | 0.41 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 17.59 | 82.93 |
Price Performance
Historical ComparisonAbout SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.